RICHARD ERIC DAVIS to Antineoplastic Agents
This is a "connection" page, showing publications RICHARD ERIC DAVIS has written about Antineoplastic Agents.
Connection Strength
0.168
-
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 09; 126(2):222-32.
Score: 0.026
-
XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells. Leuk Res. 2013 Aug; 37(8):974-9.
Score: 0.023
-
Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013 May 16; 121(20):4166-74.
Score: 0.023
-
Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program. 2013; 2013:553-60.
Score: 0.022
-
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012 Oct 18; 120(16):3260-70.
Score: 0.022
-
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011 Apr 01; 286(13):11009-20.
Score: 0.019
-
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood. 2004 Sep 01; 104(5):1428-34.
Score: 0.012
-
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2001; 2(10):RESEARCH0041.
Score: 0.010
-
Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer. 2014 Dec 15; 135(12):2834-46.
Score: 0.006
-
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res. 2005 Jan 01; 11(1):28-40.
Score: 0.003